(Q34415439)

English

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).

scientific article

Statements

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). (English)
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
Elisabeth Longchampt

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit